Key clinical point: Axicabtagene ciloleucel (axi-cel) yields high rates of response and has a favorable safety profile in previously treated indolent B-cell lymphomas.

Major finding: The overall response rate was 92%, including complete responses in 76% and a median duration of response that had not been reached at a median of 17.5 months follow-up.

Study details: Primary analysis of the phase 2 ZUMA-5 study including 146 patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Disclosures: Authors reported disclosures related to Kite, a Gilead Company; Genentech; Epizyme; Verastem; Novartis; and Pfizer.